STAT+: AACR in 30 Seconds Recap on Chinese Biotech and Oncology Comms

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and purpose

This brief summarizes reporting from STAT’s final AACR pop-up newsletter, which provided rapid highlights from the American Association for Cancer Research annual meeting.

The source is a journalistic update and not a primary research report.

Meeting focus and attendance signal

Media attention at the company’s presentations centered on data for daraxonrasib in frontline pancreatic cancer, per the source.

Revolution Medicines attracted substantial attention at AACR, with sessions described as “jam-packed” by the newsletter.

Experimental compound and proposed mechanism

Company leadership characterized RM-055 as belonging to a novel class termed “catalytic inhibitors.”

Revolution Medicines disclosed preclinical or early clinical observations for a compound designated RM-055.
The purported mechanism reported by the company is enzymatic inactivation of GTP-bound RAS (GTP-RAS) through removal of a phosphate, thereby converting active RAS to an inactive state.

Rationale and therapeutic intent highlighted

The source framed RM-055’s mechanism as potentially addressing a common resistance mechanism to RAS-directed therapies, namely amplification of mutant RAS that increases the amount of active oncoprotein and can overwhelm conventional inhibitors.
RM-055’s described catalytic activity was presented as enabling inactivation of multiple mutant RAS molecules, which the company suggested might be advantageous against RAS-dependent tumors.

Limitations and missing details

Details on methods, sample sizes, endpoints, and adverse events were not provided in the source.

The newsletter did not report study design, patient population, quantitative efficacy or safety data, stages of development, regulatory status, or independent validation of the claims.